PMID: 2507630Jul 1, 1989Paper

A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression

International Clinical Psychopharmacology
J P FeighnerG G Hendrickson

Abstract

Fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in a 6-week double-blind study among severely ill inpatients with DSM-III major depression. All but 1 patient also fulfilled criteria for melancholia. Following a 3-day placebo wash-out patients were randomly assigned to fluvoxamine, imipramine or placebo. Sixty of 81 patients completed at least 2 weeks following wash-out and were evaluated for efficacy. Analysis of covariance (controlling for baseline scores) showed significant (p less than 0.05) differences on CGI severity and BPRS total and a similar trend (p = 0.08) on the Hamilton Depression Scale. Fluvoxamine was superior (p less than or equal to 0.02) to both placebo and imipramine on these measures. Fluvoxamine's most common adverse effects were nausea and agitation. The number of fluvoxamine patients withdrawn for side-effects was less than imipramine and not significantly different than placebo. Fluvoxamine was not associated with significant changes in vital signs, ECG or laboratory tests. The results therefore indicate that fluvoxamine is a safe and highly effective treatment for hospitalized patients with major depression.

Citations

Jul 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·E A Ottevanger
Jun 12, 2002·Psychiatry Research·Kazue ShigenobuHirotaka Tanabe
Aug 22, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·C BarbuiS Garattini
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan Undurraga, Ross J Baldessarini
Mar 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·A ApterM A Riddle
Feb 25, 2009·International Clinical Psychopharmacology·David V SheehanUNKNOWN EPIC 016 Study Group
Mar 13, 1993·BMJ : British Medical Journal·F SongJ Mason
Jul 4, 2003·British Journal of Pharmacology·James T MilnesHarry J Witchel
Jul 31, 2012·Journal of Affective Disorders·Su-Jin YangTae-Youn Jun
Nov 19, 2003·Journal of Clinical Psychopharmacology·Raffaella ZanardiAlessandro Serretti
Jul 20, 2007·The Cochrane Database of Systematic Reviews·J R GeddesJ Boynton
Feb 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M HotopfG Lewis
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Ichiro M OmoriToshi A Furukawa
Apr 1, 1997·Journal of Clinical Psychopharmacology·S Kasper
Mar 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·J G EdwardsG L Pearce
Sep 8, 2017·Depression and Anxiety·Chad BeyerMichael H Bloch
Oct 1, 1995·Human Psychopharmacology·S Kasper, A Heiden
Dec 1, 1996·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R JoffeD Streiner
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
Oct 1, 1995·Human Psychopharmacology·S J Van den Berg
Oct 1, 1995·Human Psychopharmacology·B E Leonard

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.